Goldman Sachs Group Inc. grew its stake in Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 29.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 755,623 shares of the specialty pharmaceutical company’s stock after purchasing an additional 171,174 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Jazz Pharmaceuticals were worth $101,745,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. Bank of New York Mellon Corp raised its stake in Jazz Pharmaceuticals by 18.4% during the fourth quarter. Bank of New York Mellon Corp now owns 1,760,547 shares of the specialty pharmaceutical company’s stock worth $237,057,000 after acquiring an additional 274,121 shares during the period. Westfield Capital Management Co. LP raised its stake in Jazz Pharmaceuticals by 8.7% during the third quarter. Westfield Capital Management Co. LP now owns 1,438,481 shares of the specialty pharmaceutical company’s stock worth $210,378,000 after acquiring an additional 115,217 shares during the period. Renaissance Technologies LLC raised its stake in Jazz Pharmaceuticals by 2.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,244,800 shares of the specialty pharmaceutical company’s stock worth $167,612,000 after acquiring an additional 28,700 shares during the period. Boston Partners acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $161,470,000. Finally, Amundi Pioneer Asset Management Inc. raised its stake in Jazz Pharmaceuticals by 6.6% during the third quarter. Amundi Pioneer Asset Management Inc. now owns 891,322 shares of the specialty pharmaceutical company’s stock worth $130,356,000 after acquiring an additional 54,895 shares during the period. Institutional investors and hedge funds own 91.22% of the company’s stock.
In related news, SVP Paul Treacy sold 877 shares of the stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $139.62, for a total transaction of $122,446.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. Following the sale, the chief executive officer now directly owns 267,468 shares of the company’s stock, valued at $40,120,200. The disclosure for this sale can be found here. Insiders sold 11,858 shares of company stock valued at $1,745,093 over the last quarter. Insiders own 4.30% of the company’s stock.
Jazz Pharmaceuticals plc – (JAZZ) opened at $150.98 on Wednesday. The company has a quick ratio of 3.15, a current ratio of 3.29 and a debt-to-equity ratio of 0.57. The stock has a market cap of $9,209.72, a P/E ratio of 17.82, a PEG ratio of 0.81 and a beta of 0.97. Jazz Pharmaceuticals plc – has a 1-year low of $128.58 and a 1-year high of $163.75.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.73 by ($0.15). The company had revenue of $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. analysts anticipate that Jazz Pharmaceuticals plc – will post 11.43 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.themarketsdaily.com/2018/03/14/jazz-pharmaceuticals-plc-jazz-stake-raised-by-goldman-sachs-group-inc.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc – (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.